

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**Capitol Annex -Room 129**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, March 19, 2020

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Akliel<sup>®</sup> (Acne Agents, Topical)
    - ii. Nayzilam<sup>®</sup> (Anticonvulsants)
    - iii. Nourianz<sup>™</sup> (Antiparkinson's Agents)
    - iv. Reblozyl<sup>®</sup> (Erythropoiesis Stimulating Agents)
    - v. Brukinsa<sup>™</sup> (Oncology, Oral – Hematologic Cancer)
    - vi. Wakix<sup>™</sup> (Stimulants and Related Agents)
  - b. New Products to Market to be reviewed along with their respective classes:
    - i. Xenleta<sup>™</sup> (Pleuromutulins)
- V. Clinical Criteria Review – to occur within their respective full class reviews.**
  - a. Descovy for Pre-Exposure Prophylaxis (PrEP)
  - b. Hepatitis C Agents: Direct-Acting Antivirals
  - c. Soliqua (insulin glargine/lixisenatide) and Xultophy (insulin degludec/liraglutide)
- VI. Therapeutic Classes with Recommended Changes**
  - a. Antibiotics, GI
  - b. Antivirals, Oral
    - i. Antivirals: Herpes
    - ii. Antivirals: Influenza
  - c. Cephalosporins and Related Antibiotics
    - i. Antibiotics: Cephalosporins 1<sup>st</sup> Generation
    - ii. Antibiotics: Cephalosporins 2<sup>nd</sup> Generation
    - iii. Antibiotics: Cephalosporins 3<sup>rd</sup> Generation
  - d. Glucocorticoids, Inhaled
  - e. Hepatitis C Agents
    - i. Hepatitis C: Direct-Acting Antiviral Agents
    - ii. Hepatitis C: Interferons
    - iii. Hepatitis C: Ribavirins
  - f. HIV/AIDS
  - g. Hypoglycemics, Incretin Mimetics/Enhancers

- i. Diabetes: Amylin Analogue
- ii. Diabetes: DPP-4 Inhibitors
- iii. Diabetes: GLP-1 Receptor Agonists
- h. Hypoglycemics, Insulin and Related Agents
- i. Pleuromutilins

**VII. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Absorbable Sulfonamides	Hypoglycemics, Meglitinides
Antibiotics, Inhaled	Hypoglycemics, Metformins
Antibiotics, Vaginal	Hypoglycemics, SGLT2
Antifungals, Oral	Hypoglycemics, Sulfonylureas
Antihistamines, Minimally Sedating	Hypoglycemics, Thiazolidinediones (TZD)
Bronchodilators, Beta Agonist	Intranasal Rhinitis Agents
COPD Agents	Leukotriene Modifiers
Epinephrine, Self-Injected	Macrolides
Fluoroquinolones, Oral	Oxazolidinediones
Hepatitis B Agents	Penicillins
Hypoglycemics, Alpha-Glucosidase Inhibitors	Tetracyclines

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **May 21, 2020**
  - ii. **July 16, 2020**
  - iii. **September 17, 2020**
  - iv. **November 19, 2020**
- b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.